title: Secretin receptors in human pancreatic membranes.
abstract: Crude membranes (27,000 g pellets) from five normal human pancreases were prepared. In the presence of GTP, the peptides of the secretin family stimulated adenylate cyclase activity, their order of potency being: secretin greater than helodermin greater than peptide histidine isoleucinamide (PHI) greater than or equal to vasoactive intestinal peptide (VIP) greater than growth hormone releasing factor (GRF) (1-29)-NH2. In addition, helodermin and PHI were more efficient than secretin. Secretin (3-27) inhibited fully the secretin stimulation and partially only the helodermin and PHI stimulation of the enzyme. Secretin receptors were investigated by the ability of secretin and related peptides to inhibit tracer binding. [125I]Secretin binding was fully inhibited by secretin (Kd 0.8 nM), helodermin (Kd 200 nM), and PHI (Kd 250 nM). VIP and GRF(1-29)-NH2 induced partial (20%) inhibition at a high 10 microM concentration. The fragments secretin (2-27), (3-27), (4-27), and (7-27) showed the same low potency and efficacy based on their ability to stimulate adenylate cyclase and to occupy secretin receptors. The analogues [Val5]secretin and [Ala2]secretin had a higher potency than secretin. Based on this comparison of adenylate cyclase stimulation and [125I]secretin binding inhibition, it is tempting to conclude that the human pancreas: (a) possesses highly specific secretin receptors and (b) such receptors could not fully account for the whole pattern of adenylate cyclase activation by related peptides, so that the presence of an added type of "helodermin-PHI-preferring" receptors is suggested.
authors.affiliation: Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Robberecht
authors.forename: P
authors.initials: P
authors.lastname: De Neef
authors.forename: M
authors.initials: M
authors.lastname: Waelbroeck
authors.forename: J C
authors.initials: JC
authors.lastname: Camus
authors.forename: J L
authors.initials: JL
authors.lastname: Scemama
authors.forename: D
authors.initials: D
authors.lastname: Fourmy
authors.forename: L
authors.initials: L
authors.lastname: Pradayrol
authors.forename: N
authors.initials: N
authors.lastname: Vaysse
authors.forename: J
authors.initials: J
authors.lastname: Christophe
mesh_terms: D000262:Adenylyl Cyclases / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D010179:Pancreas / Q000032:analysis*; D010446:Peptide Fragments / Q000494:pharmacology; D010451:Peptide PHI / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D043562:Receptors, G-Protein-Coupled; D011964:Receptors, Gastrointestinal Hormone / Q000032:analysis* / Q000187:drug effects; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D010446:Peptide Fragments; D010451:Peptide PHI; D010455:Peptides; D043562:Receptors, G-Protein-Coupled; D011964:Receptors, Gastrointestinal Hormone; C029937:secretin receptor; D014660:Vasoactive Intestinal Peptide; C040442:heliodermin; D000262:Adenylyl Cyclases